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httpcense.Abstract Background: Radiofrequency (RF) catheter ablation is a well established approach in
treating several types of cardiac arrhythmias whether supraventricular or ventricular and is in many
cases the ﬁrst choice therapy. Radiofrequency ablation has been shown to be effective and safe with
a success rates ranging from 80% to 100%.
Furthermore, few studies had investigated the efﬁcacy and safety of catheter ablation in elderly
patients and pediatrics patients.
Objectives: This study is prospective evaluation of the safety and efﬁcacy of radiofrequency abla-
tion of regular narrow complex supraventricular tachycardia in both age extremes, elderly and
pediatric patients.
Methods: The study included 30 patients, 19 patients >60 years [group I] and 11 pediatric
patients <14 years [group II], referred to National Heart Institute and Critical Care Department
at Kasre AL-Ainy Cairo University hospital from October 2008 to October 2009 who underwent
electrophysiological study and radiofrequency catheter ablation to symptomatic supraventricular
tachyarrhythmia, medically refractory.
Results: Thirty patients had ablated presented with variable clinical characteristics in both
groups. The AVRT is more frequent in higher age group however the AVNRT is almost equally
distributed in both age group only two cases atrial ﬂutter and atrial tachycardia. The success rate
in group I was 90% and in group II was 100%. No complications were recorded in group I and in
group II the only recorded complication was complete heart block in one patient that required per-
manent pacemaker insertion, also recurrence rate was zero in group two but two patients in group
one show recurrence at 6 months follow up.com (W.A. El-Latief).
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96 W.A. El-Latief et al.Conclusion: We have concluded that catheter ablation of supraventricular tachycardia is a very
good option for management of patients with drug resistant SVT in both young and old patients.
The success rate was very high almost with no complications and very low recurrence rate in the
elderly and no recurrence in the young during the 6 months follow-up.
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Paroxysmal supraventricular tachycardia incidence is approxi-
mately 1–3 cases per 1000 persons. The incidence rate of the
WPW pattern on ECG tracings is 0.1–0.3% in the general
population, although not all patients develop SVT [1]. In a
population-based study, the prevalence of paroxysmal supra-
ventricular tachycardia was 2.25 cases per 1000 persons, with
an incidence of 35 cases per 100,000 person-years [2]. AVNRT
is more common in patients who are of middle age or older,
while adolescents are more likely to have SVT mediated by
an accessory pathway. Paroxysmal supraventricular tachycar-
dia is not only observed in healthy individuals, it is also com-
mon in patients with previous myocardial infarction, mitral
valve prolapse, rheumatic heart disease, pericarditis, pneumo-
nia, chronic lung disease, and current alcohol intoxication.
Digoxin toxicity also may be associated with paroxysmal
supraventricular tachycardia [3].
Radiofrequency (RF) catheter ablation is a well established
approach in treating several types of cardiac arrhythmias
whether supraventricular or ventricular and is in many cases
the ﬁrst choice therapy. Radiofrequency ablation has been
shown to be effective and safe with a success rates ranging
from 80% to 100% in patients with atrial ﬂutter and exceeding
90–95% in patients with atrioventricular nodal re-entrant
tachycardia (AVNRT) or atrioventricular re-entrant tachycar-
dia (AVRT) due to accessory pathways [4,5].
The incidence of procedural complications ranges from
25% to 6% in different cases series [6–8].
Despite such encouraging data, the interventional approach
in treating cardiac arrhythmia has not been widely adopted in
elderly people, even though it may be particularly useful in this
kind of patient, in whom antiarrhythmic drugs are often
poorly tolerated [9].
Indeed, the age related structural modiﬁcation of the heart;
the higher prevalence of structural heart disease and the higher
thromboembolic risk are believed to increase of procedural
complications in the elderly patients in comparison with young
adults [10].
Furthermore, few studies had investigated the efﬁcacy and
safety of catheter ablation in elderly patients and pediatrics
patients [11,12].Aim of this study
This study is prospective evaluation of the safety and efﬁcacy
of radiofrequency ablation of regular narrow complex supra-ventricular tachycardia in both age extremes, elderly and pedi-
atric patients.
Study population
The study included 30 patients, 19 patients >60 years [group I]
and 11 pediatric patients <14 years [group II], referred to Na-
tional Heart Institute and Critical Care Department at Kasre
AL-Ainy Cairo University hospital fromOctober 2008 to Octo-
ber 2009 who underwent electrophysiology study and radiofre-
quency catheter ablation to variable indications. The inclusion
criteria were: life-threatening symptomatic supraventricular
tachyarrhythmia, medically refractory tachycardia, adverse
drug effects, impending surgery, and the patient’s choice.
Methodology
Study protocol
All patients included in the study were subjected to the following
1. Full history taking with special emphasis on the history of
dysrrhythmias.
2. Full clinical examination.
3. 12 – leads resting ECG.
4. Twenty-four hour – dynamic ECG monitoring [Holter] to
document the presence of dysrrhythmias.
5. Transthoracic echocardiography [TTE] for assessment of
the cardiac dimensions, evaluation of the presence of any
anatomical abnormalities and assessment of LV systolic
and diastolic function.
6. Routine laboratory investigations including complete blood
picture, liver and kidney function tests, lipid proﬁle, thyroid
function tests and hepatitis markers.
7. Radiofrequency catheter ablation:
 Patients were brought to the electrophysiology labora-
tory in the post – absorptive state and always off anti-
arrhythmic drugs for ﬁve half lifes.
 In all cases, 6 French quadpolar catheters were inserted
through right and left femoral veins and positioned in
the his bundle region and the right ventricular apex.
 A 6 French quadpolar catheter was then inserted thro-
ugh the left subclavian vein and positioned in the coro-
nary sinus.
 In the atrial ﬂutter ablation procedure, a 7 French Halo
catheter was inserted through the left femoral vein and
positioned in the right atrium.
Figure 1 Cardiac co-morbid condition of the two groups, P
value =<0.05.
Figure 2 Non-cardiac co-morbid condition of the two groups, P
value =<0.05.
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recording by general electric-PRUCA engineering and
simulation techniques by Micropace, EPS 320, cardiac
stimulator (Cordis) was performed to conﬁrm diagnosis
and to identify the target site for radiofrequency delivery.
 Radiofrequency energy was applied through a 7-french
4-mm tip catheter in procedures for AVNRT, AVRT
and AT and through a 7-french 8-mm tip catheter in
cases of atrial ﬂutter.
 The ablating catheter was inserted through the right f-
emoral vein in procedures for AVNRT, right accessory
pathways and AT.
 The patients with left accessory pathways, the ablating
catheter was inserted through the right femoral artery,
atrial septal puncture and left atrial approach was used
in case of retrograde approach failure.
 Radiofrequency energy was applied by using an RF cur-
rent generator for a time ranging from 30 to 120 s, with
a maximum tip temperature of 60–65 C and a power
output of 50 W, ablator: ST 1642 – EP – Shuttle-Stoc-
kert (Cordis).
Results
Clinical characteristics: group I had a signiﬁcantly higher prev-
alence of cardiovascular and non-cardiovascular comorbid
conditions (P< 0.05) Table 1, Figs. 1 and 2.
Table 2 showed that the most commonly used drug therapy
was calcium channel blockers then beta blockers. The inci-
dence of the use of Cordarone, B-blockers and aspirin were
signiﬁcantly higher among group I than that of group II
(P< 0.05).
The mean tachycardia duration were signiﬁcantly higher in
group I than that of group II (P< 0.001).
Frequency of dysrrhythmia per year in the two groups
There was no signiﬁcant different as regards frequency of dysr-
rhythmia of both groups (Table 3) and (Fig. 3)
Table 4 show that the AVRT is more frequent in higher age
group; however the AVNRT is almost equally distributed in
both age group.Table 1 Clinical characteristic of both groups.
Group I Group II P value
N % N %
Cardiac conditions
None 7 36.84 9 81.82 <0.05
Valvular 5 26.32 2 18.18
HTN 5 26.32 0 0.00
Other 2 10.53 0 0.00
Non cardiac conditions
None 12 63.16 9 81.8 <0.05
COPD 2 10.53 2 18.2
Dyslip 2 10.53 0 0.00
Diabetes 2 10.53 0 0.00
Epilepsy 1 5.26 0 0.00Table 5 show that: slow pathway ablation was the only site
for AVNRT ablation in both groups but the left lateral acces-
sory pathway was the target of ablation in most AVRT pa-
tients in both groups, and only two patients in group 1 need
antiarrhythmics for non-speciﬁc atrial tachycardia after
ablation.
Fluoroscopy time was more prolonged in group I and abla-
tion duration was longer also in group I (with signiﬁcant P
value): Table 6, Figs. 4 and 5.
No complications recorded in group I and in group II apart
from complete heart block in 1 patient that required perma-
nent pacemaker insertion (Table 7).
No recurrence rate recorded in group II at 1 or 6 months
follow- up period in group II while in group I the recurrence
occurred in 2 patients at 6 months follow up (10.53%) (Table
8).
The following Figs. 6–8 show intracardiac tracing for pa-
tients with AVRT and AVNRT during radiofrequency
ablation.
Discussion
Accessory pathway mediated tachycardias constitute 80% of
all the tachyarrhythmias during infancy. In some infants, some
tachycardias they resolve as the child grows. Most SVTs
Table 5 Catheter ablation data of the 2 groups.
Group I Group II P value
N % N %
Ablation site
Focal AT (LASSO) 1 5.26 0 0.00 >0.05
Isthmus dependent A. Fl 1 5.26 0 0.00
LL Ap 6 31.58 4 36.36
Lps Ap 0 0.00 1 9.09
Rl Ap 1 5.26 0 0.00
Slow pathway 10 52.63 6 54.55
Access site
Right 12 63.16 7 63.64 >0.05
Left 1 5.26 2 18.18
Both 6 31.58 2 18.18
Catheter number
4 4 21.05 3 27.27 >0.05
5 15 78.95 8 72.73
Trans-septal 4 21.05 3 27.27 >0.05
Arterial 6 31.58 3 27.27 >0.05
Mode of initiation
Spontaneous 6 31.58 2 18.18 >0.05
Atrial pacing 10 52.63 4 36.36
Extra stimulus 3 15.79 5 45.45
Mode of termination
Spontaneous 3 15.79 3 27.27 >0.05
Overdrive 4 21.05 2 18.18
DC shock 7 36.84 1 9.09
Ablation 5 26.32 5 45.45
Post ablation test
Yes 19 100.00 11 100.00 NA
NO 0 0.00 0 0.00
Drug test
Yes 13 68.42 8 72.73 >0.05
NO 6 31.58 3 27.27
Post ablation antiarrhthmics
Yes 2 10.53 0 0.00 NA
NO 17 89.47 11 100.00
Table 2 Drug therapy before ablation in the two groups.
Group I N= 19 Group II N= 11 P value
N % N %
Cordarone 13 68.42 0 54.5 <0.05
B-blockers 11 57.9 8 72.7 <0.05
Ca-blockers 16 84.2 9 81.8 >0.05
ACE 10 52.6 0 0 NA
ARBs 4 21 0 0 NA
Statins 8 42.1 0 0 NA
Aspirin 19 100 6 54.5 <0.001
Anti-coagulant 3 15.8 0 0 NA
NA= not applicable.
Figure 3 Frequency of tachycardia per year in the two groups.
Table 4 Distribution of SVT in both groups.
Type of S.V.T Group I
(>60 years)
Group II
(<14 years)
AVNRT 10 (52.6%) 6 (54.5%)
AVRT 7 (36.8%) 5 (45.5%)
1. Left lateral AP 6 4
2. Right lateral AP 1 0
3. Left posteroseptal AP 0 1
A. Flutter 1 (5.3%) 0 (0%)
Atrial tachycardia 1 (5.3%) 0 (0%)
Table 3 Frequency of dysrrhythmia per year in the 2 groups.
Group I N= 19 Group II N= 11 P value
N % N %
More than 12 5 26.32 0 0.00 NA
Less than 12 14 73.68 11 100.00
Total 19 100.00 11 100.00 30
NA= not applicable.
98 W.A. El-Latief et al.beyond the age of 5 tend to recur and may need to undergo RF
ablation. Ectopic atrial tachycardia and atrial ﬂutter represent10–15% of SVTs in infancy, of which some may not ever recur
[13].
Radiofrequency ablation is uncommonly performed under
5 years of age. This is because some SVTs resolve spontane-
ously. Also, arrhythmias may get suppressed under the
Table 6 Cycle length, ablation duration and ﬂuoroscopy time
in the 2 groups.
Group I N= 19 Group II N= 11 P value
Cycle length
(mean ± SD)
334.7 ± 32 338.1 ± 33.1 >0.05
Ablation duration
(mean ± SD) (sec.)
110.7 ± 21.3 87.5 ± 18.7 <0.01
Fluoroscopy time 41.8 ± 2.3 20.6 ± 1.8 <0.001
Table 7 Complications recorded during ablation in the 2
groups.
Group I N= 19 Group II N= 11
N % N %
Hematoma 0 0 0 0
Infection 0 0 0 0
Eﬀusion 0 0 0 0
Embolization 0 0 0 0
Coronary thrombus 0 0 0 0
Complete heart block 0 0 1 9
Dissection 0 0 0 0
DVT 0 0 0 0
Death 0 0 0 0
Total 0 0 1 9
Figure 5 Fluoroscopy time in the two groups.
Figure 4 Ablation duration in the two groups.
Table 8 Recurrence rate at 1 and 6 months follow-up.
Group I N= 19 Group II N= 11
N % N %
1 month follow-up 0 0 0 0
6 months follow-up 2 10.53 0 0
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poses limitations in using multiple electrode catheters and
there is an increased possibility of cardiac/valve damage with
ablation. The risks of ablation are acceptable only if the child
has recurrent, drug-resistant SVT especially if it results in
tachycardiomyopathy or life-threatening cardiovascular com-
promise [14].
Cardiac arrhythmias are relatively uncommon in the youn-
ger population, accounting for approximately 5% of all emer-
gency cardiac admissions. Paroxysmal supraventricular
tachycardia (SVT) like atrio-ventricular reciprocating tachy-
cardia (AVRT), ectopic atrial tachycardia, and atrio-ventricu-
lar nodal reentrant tachycardia are the most common. In those
patients who have undergone operations for congenital heart
disease, junctional ectopic tachycardia and atrial ﬂutter are
more common. Symptoms of arrhythmias depend on the
age, presence of structural heart disease, and the state of the
left ventricular function apart from the nature, severity, and
duration of arrhythmia [15].
Atrioventricular nodal re-entry is the most common cause
of regular narrow complex SVT. In our study, 70% of SVT
are due to atrioventricular nodal re-entry. If AVNRT are less
frequent and responsive to therapy with beta blocker or cal-
cium channel blocker, then RFA can be deferred [16].
Supraventricular tachycardias are the most frequent forms
of symptomatic tachyarrhythmias in infants, children and
adolescents. Clinical symptoms depend on age and underlying
cardiac anatomy. Newborn babies and infants with paroxys-
mal atrioventricular reentrant tachycardias usually present
with signs of congestive heart failure due to rapid heart rate
[17].
Failure to discriminate among AF, atrial ﬂutter, and other-
supraventricular arrhythmias has complicated the precise def-
inition of this arrhythmia in the general population. The
estimated prevalence of paroxysmal supraventricular tachycar-
dia (PSVT) in a 3.5% sample of medical records in the Marsh-
ﬁeld (Wisconsin) Epidemiologic Study Area (MESA) was 2.25
per 1000. The incidence of PSVT in this survey was 35 per 100
000 person-years [18].
In our study, we conducted a prospective clinical trial in the
National Heart Institute and critical care department at Kasr
Al-Ainy Cairo University hospital in order to evaluate the
safety and the efﬁcacy of radiofrequency ablation in both
age extremes, elderly and pediatric patients.
Our study included 30 patients; 19 patients >60 years of
age (group I) and 11 pediatric patients (group II).
Group I included 19 patients, their age ranged between 61
and 71 years with a mean age of 67.5 ± 5.1 years, they were
9 males (47.4%) and 10 females (52.6%) while in group II, their
mean age was 12.5 ± 3.5 years and they were 6 males (54.5%)
and 5 females (45.6%). There was no signiﬁcant difference be-
Figure 6 Intracardiac tracing showing surface L1and V2 (preexcited) and shortest AV in PCS (in sinus rhythm) denoting the presence of
antegrade conduction via Lt posteroseptal AP. RF ablation was applied via the ablation catheter which recorded shortest AV than that of
PCS catheter.
100 W.A. El-Latief et al.tween the 2 groups regarding their sex distribution (P> 0.05).
The heart rate was signiﬁcantly higher among group II than
that of group I but the systolic and diastolic blood pressure
was signiﬁcantly higher among group II than that of group I
(P< 0.05).
Results of the current study showed that group I had a sig-
niﬁcantly higher prevalence of cardiovascular and non-cardio-
vascular comorbid conditions (P< 0.05).
Results of the current study showed the most commonly
used drug therapy was calcium channel blockers then beta
blockers. The incidence of the use of Cordarone, B-blockers
and aspirin were signiﬁcantly higher among group I than that
of group II (P< 0.05).
Results of the current study showed the mean tachycardia
duration were signiﬁcantly higher than in group I than that
of group II (P< 0.001).
Results of our study showed that no complications re-
corded in group I and in group II the only recorded complica-tion was complete heart block in 1 patient that required
permanent pacemaker insertion.
In our study there was no recurrence rate recorded in group
II at 1 and 6 months follow up in group II, while in group I the
recurrence occurred in 2 patients at 6 months follow up
(10.53%).
However in patients with frequent episodes or hemody-
namic intolerance or those who refuse prolonged medication,
RFA is a safe and cost effective treatment modality. The suc-
cess rate is more than 96% and the risk of damaging the
compact AV node is <1% and the recurrence rate is also
<3% [19]. But in our study may be explained by small number
of patients and the recurrence rate in AVNRT has been very
low because it had been part of our protocol to look for slow
junctional rhythm during RFA and to insure with isoprotero-
nol the tachycardia could no longer be reinduced once RFA
had been done. The presence of a junctional rhythm during
slow-pathway ablation has been indisputably considered to
Figure 7 During RF ablation, slow junctional rhythm denoting potential successful ablation in patient with AVNRT from group I.
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ablation.
In our study we found that RF ablation was safe in children
with a very high success rate and very low complication rate
and these results are not in agreement with Hsieh et al. [20]
who stated that children were not considered for radiofre-
quency ablation because is not very safe in this age and
cryo-ablation is a preferable option for AVNRT.
Our results are different from the study of Shuenn-Nan et
al. [21] who studied 27 patients (17 males, 10 females) under-
went RFA at an age less than 6 years. All of his patients had
drug-refractory SVT or tachycardia-induced cardiomyopathy.
They found that immediate success rate was 92.6%, with low
early (3.7%) and late recurrence (7.4%) after 5.4 ± 3.7 years
follow-up. Tachycardia-induced cardiomyopathy was notedin 4 and resolved in all after RFA. Procedure-related compli-
cations included complete atrioventricular block in 1. No other
risk factors for outcomes were noted, even with low body
weight. He concluded that the outcome of RFA for medically
refractory SVT, even associated with tachycardia-induced car-
diomyopathy, in infants is favorable [21]. The higher recur-
rence rate and lower success rate in their study may be
because they included younger patients and longer follow up
period.
Results of our study showed that RF ablation of young
children was a good and safe way of management of patients
with SVT and these results agreed with that reported by Van
Hare, [22] who stated that long-term management of AVRT
in infancy and childhood is age dependent. In newborn babies
and infants, pharmacological therapy is advised due to the
Figure 8 Normalization during RF application as evidenced by the QRS complex is no more preexisted and prolongation of AV interval
in pt with Lt posterolateral AP (target site of ablation at MCS).
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end of the ﬁrst year of life. In contrast to this, the probability
of spontaneous cessation of tachycardia in children >1 year of
age is very low. Therefore, radiofrequency catheter ablation of
the anatomical substrate of the tachycardia is a rational
alternative to long-lasting antiarrhythmic therapy.
Our results are also in agreement with the study of Aiyagari
et al. 2005 [23] who found that RFA in children with a struc-
turally normal heart are comparable to those achieved in
adults.
Paul et al. [17] supported our conclusion in that pharmaco-
logical therapy is often not sufﬁcient to control the tachycar-
dia. In addition, underlying sinus node dysfunction may be
aggravated in a considerable portion of the patients affected.
Also Baine et el. [24] supported our conclusion as supraven-
tricular arrhythmias are relatively common, often repetitive,
occasionally persistent, and rarely life threatening. The precip-
itants of supraventricular arrhythmias vary with age, sex, and
associated comorbidity [24].Age exerts an inﬂuence on the occurrence of SVT. The
mean agent the time of PSVT onset in the MESA (Multi Eth-
nic Study of Atherosclerosis) cohort was 57 years (ranging
from infancy to more than 90 years old) [2]. In the MESA
population, compared with those with other cardiovascular
disease, ‘‘lone’’ (no cardiac structural disease) PSVT patients
were younger (mean age equals 37 versus 69 years), had faster
heart rates (186 versus 155 beats per minute [bpm]), and were
more likely to present ﬁrst to an emergency room (69% versus
30%). The age of tachycardia onset is higher for AVNRT (32
plus or minus 18 years) than for AVRT (23 plus or minus
14 years) [2].
Gender plays a role in the epidemiology of SVT. Female
residents in the MESA population had a two-fold greater rel-
ative risk (RR) of PSVT (RR equals 2.0; 95% conﬁdence inter-
val equals 1.0–4.2) compared with males [2].
In our study we targeted the slow pathway along the pos-
terolateral region of the tricuspid annulus which yielded a high
success rate and a low complication rate (only one patient had
complete heart block, and our results are in agreement with
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ing the slow pathway along the posteroseptal region of the tri-
cuspid annulus markedly reduces the risk of heart block and is
the preferable approach. Advantages of slow-pathway abla-
tion include a lower incidence of complete AV block (1% ver-
sus 8%) and the absence of the hemodynamic consequences of
marked prolongation of the PR interval. Hence, slow pathway
ablation is always used initially and fast pathway ablation is
considered only when slow pathway ablation fails.
Our results are also in agreement with the NASPE prospec-
tive catheter ablation registry which included 1197 patients
who underwent AV-nodal modiﬁcation for AVNRT. Success
was achieved in 96.1%, and the only signiﬁcant complication
was a 1% incidence of second-degree or third-degree AV block
[25]. These data have been conﬁrmed by Clague et al. [26].
Atrioventricular block may complicate slow-pathway ablation
caused by posterior displacement of the fast pathway, superior
displacement of the slow pathway (and coronary sinus), or
inadvertent anterior displacement of the catheter during RF
application. Pre-existing ﬁrst-degree AV block does not appear
to increase appreciably the risk of developing complete AV
block, although caution is advised. The recurrence rate after
ablation is approximately 3–7% [27].
Ablation of the slow pathway may be performed in patients
with documented SVT (which is morphologically consistent
with AVNRT) but in whom only dual AV-nodal physiology
(but not tachycardia) is demonstrated during electrophysiolog-
ical study [18].
Slow-pathway ablation may be considered at the discretion
of the physician when sustained (more than 30 s) AVNRT is
induced incidentally during an ablation procedure directed at
a different clinical tachycardia [18].
Indications for ablation depend on clinical judgment and
patient preference. Factors that contribute to the therapeutic
decision include the frequency and duration of tachycardia,
tolerance of symptoms, effectiveness and tolerance of antiar-
rhythmic drugs, the need for lifelong drug therapy, and the
presence of concomitant structural heart disease. Catheter
ablation has become the preferred therapy, over long-term
pharmacologic therapy, for management of patients with
AVNRT. The decision to ablate or proceed with drug therapy
as initial therapy is, however, often patient speciﬁc, related to
lifestyle issues (e.g., planned pregnancy, competitive athlete,
recreational pilot), affected by individual inclinations or aver-
sions with regard to an invasive procedure or the chronicity of
drug therapy, and inﬂuenced by the availability of an experi-
enced center for ablation. Because drug efﬁcacy is in the range
of 30–50%, catheter ablation may be offered as ﬁrst-line
therapy for patients with frequent episodes of tachycardia.
Patients considering RF ablation must be willing to accept
the risk of AV block and pacemaker implantation [18].
Catheter ablation of accessory pathways is performed in
conjunction with a diagnostic electrophysiological test. The
purposes of the electrophysiological test are to conﬁrm the
presence of an accessory pathway, determine its conduction
characteristics, and deﬁne its role in the patient’s clinical
arrhythmia. Once the arrhythmia is identiﬁed, ablation is per-
formed using a steerable ablation catheter. There have been no
prospective, randomized clinical trials that have evaluated the
safety and efﬁcacy of catheter ablation of accessory pathways
versus pharmacological treatment, however, the results of
catheter ablation of accessory pathways have been reportedin a large number of single-center trials, one multicenter trial
[27] and several prospective registries [25]. The initial efﬁcacy
of catheter ablation of accessory pathways is approximately
95% in most series [27]. The success rate for catheter ablation
of left free-wall accessory pathways is slightly higher than for
catheter ablation of accessory pathways in other locations.
After an initially successful procedure, resolution of the
inﬂammation or edema associated with the initial injury allows
recurrence of accessory pathway conduction in approximately
5% of patients. Accessory pathways that recur can usually be
successfully ablated during a second session [18].
Complications associated with catheter ablation of acces-
sory pathways result from radiation exposure, vascular access
(e.g., hematomas, deep venous thrombosis, arterial perfora-
tion, arteriovenous ﬁstula, pneumothorax), catheter manipula-
tion (e.g., valvular damage, microemboli, perforation of the
coronary sinus or myocardial wall, coronary artery dissection,
thrombosis), or delivery of RF energy (e.g., AV block, myocar-
dial perforation, coronary artery spasm or occlusion, transient
ischemic attacks, or cerebrovascular accidents). The proce-
dure-related mortality reported for catheter ablation of acces-
sory pathways ranges from 0% to 0.2% [25]. The voluntary
Multicenter European Radiofrequency Survey (MERFS)
reported data from 2222 patients who underwent catheter
ablation of an accessory pathway. The overall complication
rate was 4.4%, including 3 deaths (0.13%). The 1995 NASPE
survey of 5427 patients who underwent catheter ablations of
an accessory pathway reported a total of 99 (1.82%) signiﬁcant
complications, including 4 procedure-related deaths (0.08%).
Among the 500 patients who underwent catheter ablation of
an accessory pathway as part of a prospective, multicenter
clinical trial, there was 1 death (0.2%). This patient died of dis-
section of the left main coronary artery during an attempt at
catheter ablation of a left free-wall accessory pathway [25].
The most common major complications are complete AV
block and cardiac tamponade. The incidence of in advertent
complete AV block ranges from 0.17% to 1.0%. Most occur
in the setting of attempted ablation of septal accessory path-
ways located close to the AV junction. The frequency of car-
diac tamponade varies between 0.13% and 1.1%.
The higher incidence of complications in the previously
mentioned study could be explained by that, they included a
larger number of patients and at longer duration of the study
as well as the bigger number of operators.Conclusion
Catheter ablation of supraventricular tachycardia is a very
good option for management of patients with drug resistant
SVT in both young and old patients.
The success rate was very high almost with no complica-
tions and very low recurrence rate in the elderly and no recur-
rence in the young during the 6 months follow-up.
Older patients had more comorbid conditions with longer
duration of ablation and higher energy frequency as well as
more ﬂuoroscopic time.References
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